Trial Profile
Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2009 Planned end date changed from 1 Nov 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 27 Oct 2009 Interim results reported in GlaxoSmithKline media release.